Clinical trials
Hepatic Arterial Infusion Chemotherapy clinical trials
Below are recruiting hepatic arterial infusion chemotherapy clinical trials, each written for real people, not researchers. We’re tracking 37 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06187961RecruitingPhase 2
Combination therapy for liver cancer that cannot be removed with surgery
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Wuhan, HubeiAges 18 years+ - NCT07764497RecruitingPhase 2
Chemotherapy through liver artery for colorectal cancer that spread to liver
This trial tests giving chemotherapy directly into the liver artery for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to shrink the tumors and make the liver healthy enough for surgery.
Toronto, OntarioAges 18 years+ - NCT06632093Recruiting
Combination therapy for advanced liver cancer after standard treatment fails
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
Shenyang, LiaoningAges 18–75 - NCT03364530RecruitingPhase 2
Liver artery chemotherapy for non-surgical bile duct cancer
This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.
AmiensAges 18 years+ - NCT06742424RecruitingPhase 2
PD-L1 antibody + bevacizumab + liver chemo for advanced liver cancer
This trial tests whether combining a PD-L1 antibody (an immunotherapy) with bevacizumab (a drug that slows blood vessel growth to tumors) and a liver-directed chemotherapy infusion can help people with advanced liver cancer that has spread outside the liver. It is designed for patients who have not previously received these specific treatments.
Chengdu, SichuanAges 18–75 - NCT06988852RecruitingPhase 2
Chemo infusion into liver for colorectal cancer spread
This trial tests a strong chemotherapy combination given directly into the liver's blood supply (called HAIC) for people whose colorectal cancer has spread only to the liver and cannot be removed with surgery yet. The goal is to shrink the liver tumors enough so they can be surgically removed.
Wuhan, HubeiAges 18–75 - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07327788RecruitingPhase 2
Study of QL1706, bevacizumab, and chemo infusion for liver cancer with portal vein clot
This trial tests a combination of three treatments for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this therapy can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06796803RecruitingPhase 2/Phase 3
Combination therapy before surgery for liver cancer
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Harbin, HeilongjiangAges 18–75 - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+ - NCT06333561Recruiting
Combination therapy for infiltrative liver cancer
This trial tests a three-drug combination for a specific type of liver cancer called infiltrative hepatocellular carcinoma. It combines a liver-directed chemotherapy infusion (HAIC) with two oral and intravenous drugs (lenvatinib and a PD-1 inhibitor) to see if it works better than lenvatinib alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT06420440RecruitingPhase 2
Pre-surgery treatment for liver cancer at high risk of return
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
Xiangyang, HubeiAges 18–75 - NCT06519578Recruiting
Liver Cancer Study: Comparing Two Chemotherapy Drugs via Artery Infusion
This study compares two chemotherapy drugs (raltitrexed and 5-fluorouracil) given directly into the liver's main artery to treat liver cancer. It aims to see which drug works better and is safer for people with hepatocellular carcinoma.
ShanghaiAges 18–75 - NCT06632717RecruitingPhase 2
Chemo through liver artery with lipiodol for advanced liver cancer
This trial tests giving chemotherapy directly into the liver artery (HAIC) mixed with a special oil called lipiodol. It may help people with advanced liver cancer that cannot be treated with standard methods or who cannot tolerate them.
TaipeiAges 20 years+ - NCT06741020RecruitingPhase 1/Phase 2
Chemo and Immunotherapy before Liver Cancer Surgery
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
Hangzhou, ZhejiangAges 18–75 - NCT06857773RecruitingPhase 3
Combined pump therapy and chemo for liver-only colorectal cancer
This trial tests a treatment approach where you receive chemotherapy directly into your liver through a surgically placed pump, combined with standard systemic chemotherapy (given through a vein). The goal is to shrink liver tumors enough so they can be removed later with surgery. It is for people whose colorectal cancer has spread only to the liver and has not been treated before.
AmsterdamAges 18 years+ - NCT06859684RecruitingPhase 2
Triple therapy for advanced bile duct cancer of the liver
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
Chengdu, SichuanAges 18–75 - NCT06888063RecruitingPhase 2
Chemo pump into the liver for bile duct cancer that can be surgically removed
This trial tests whether giving extra chemotherapy directly to the liver through a small pump (called HAIP) before or after surgery can improve outcomes for patients with bile duct cancer inside the liver. It is for patients whose cancer is considered removable by surgery.
Rotterdam, South HollandAges 18 years+ - NCT06904170RecruitingPhase 2/Phase 3
Immunotherapy with or without liver artery chemo for liver cancer
This trial tests adding a targeted chemo infusion into the liver's main artery to two immunotherapy drugs for liver cancer. It may help patients whose cancer has spread within the liver and can't be removed by surgery.
BordeauxAges 18 years+ - NCT07062055RecruitingPhase 2
A study of combination therapy for advanced liver cancer with spread
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
Jinan, ShandongAges 18–70 - NCT07070076Recruiting
Y-90 therapy vs chemo infusion for liver cancer
This study compares two liver-directed treatments—radioactive Yttrium-90 beads (SIRT) and a type of chemo infusion directly into the liver (HAIC)—for people whose liver cancer is advanced enough to need treatment but might still be removable with surgery. The goal is to see which approach can shrink the tumor best before surgery.
Guangzhou, GuangdongAges 18–75
Hear when a new Hepatic Arterial Infusion Chemotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatic arterial infusion chemotherapy?
- Yes. Clin2 currently lists 37 recruiting hepatic arterial infusion chemotherapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatic arterial infusion chemotherapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatic arterial infusion chemotherapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.